Vimarsana
Biggest News Aggregation in the World

Page 13 - Topline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Today - Breaking & Trending Today

Lipocine : LPCN 1154 Topline Results - PK Bridge Clinical Study - Vimarsana News

Lipocine : LPCN 1154 Topline Results - PK Bridge Clinical Study

LPCN 1154 Oral Neuroactive Steroid for Depression Disorders Topline Results PK Bridge Clinical... | May 17, 2023

Dermavant Sciences: Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old - Vimarsana News

Dermavant Sciences: Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-ADTM response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights - Zynerba - Vimarsana News

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights - Zynerba

*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old - Vimarsana News

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10th consecutive... | May 16, 2023

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results - Vimarsana News

Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results

Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif.,... | May 11, 2023